Skip to content
Thursday 3 September 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,796.19
+0.37%
DAX
25,827.37
-0.05%
CAC 40
8,244.56
-0.44%
STOXX 50
6,348.19
-0.22%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Wednesday 30 December 2020 8:37 am  |  Updated:  Wednesday 30 December 2020 8:39 am

Over by Spring: Hancock hails Oxford/AstraZeneca jab as part of path to normality

By: James Silver

Add as a preferred source on Google
Chelsea Pensioners Receive Covid-19 vaccine
(Photo by Aaron Chown - WPA Pool/Getty Images)

Health Secretary Matt Hancock said the UK could expect to be out of the pandemic by spring after the Oxford/AstraZeneca jab was approved.

Boss of the pharmaceutical firm Pascal Soriot said as many as 2m vaccines could be manufactured each week.

“The vaccine is our way out of this,” the Health Secretary told the BBC.

Read more: Oxford/AstraZeneca jab approved

“Whereas previously I’ve I hoped we’d be out of this by spring, I now have a high degree of confidence we’ll be out of this by spring,” he said.

The vaccine rollout will be stepped up, Hancock promised, with data suggesting that a first jab offers significant immunity from Covid-19 and a booster jab required for longer-term protection.

Soriot meanwhile said that the Government’s rollout target of 1m jabs a week could be beaten.

The UK has pre-ordered 100m doses of the jab, and Soriot said the firm had already produced “millions.”

“It is a massive logistical effort to inject so many people, but we will ramp up deliveries over the next two or three weeks.”

Read more

Budget supermarket Iceland’s sneaky jab at Big Four management consultants

Iceland has reported its latest financial results.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Coronavirus

Trending Articles

  • Vodafone and Deliveroo look to patch up Reform ties after Yusuf prison threats

  • Trio of firms poised to quit London Stock Exchange as exodus gathers pace

  • Jim O’Neill: Capital gains tax hike ‘looms’ as top option for Burnham

  • Easyjet’s over-60s recruitment push is economically necessary

  • ‘Large tax hikes on the way’: How the global bond rout is boxing in Healey

More from Morning Wire

  • Budget supermarket Iceland’s sneaky jab at Big Four management consultants

    Retail
    Iceland has reported its latest financial results.
  • Astrazeneca and Jaguar Land Rover given power to endorse talented migrants for visas

    Politics
    Jonathan Reynolds addressing the SMMT's annual International Automotive Summit (image courtesy of SMMT)
  • Astrazeneca explores $400bn megadeal with US rival 

    Markets
    AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.
  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
  • As it happened: UK stocks cool after Astrazeneca drags; Trump and Iran clash over peace talks

    FTSE 100 Live
    Donald Trump speaking at a desk, gesturing with hands, wearing a dark suit and red tie.
  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • ISG Event to Spotlight Strategies for the AI-Driven Autonomous Enterprise

    Business Wire
  • As it happened: FTSE 100 jumps as oil falls back; Warsh says ‘work to do’ on inflation

    FTSE 100 Live
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook